A subgroup of patients with osteosarcoma — a form of bone cancer — could be helped by an existing drug, suggest scientists. In the largest genetic sequencing study of osteosarcoma to date, scientists discovered that 10 percent of patients with a genetic mutation in particular growth factor signalling genes may benefit from existing drugs, known as IGF1R inhibitors.